---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-279097"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:27:51.093276+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Atea Pharma reports Q3 net loss $8.1M; cash $665M; SUNRISE-3 enrollment imminent

## Summary
- Net loss of $8.1M ($0.10 per share) vs net loss of $28.2M in Q3 2021.
- Cash and marketable securities $665.0M at Sept 30, 2022, down from $764.4M at Dec 31, 2021.
- R&D expenses fell to $4.9M from $43.0M, aided by a $14.5M credit from Roche cost share close-out.
- SUNRISE-3 Phase 3 trial for bemnifosbuvir in high-risk COVID-19 patients expected to start enrollment before year-end 2022.
- AT-752 human challenge study and DEFEND-2 first cohort completion expected around year-end; HCV trial submission also anticipated.

## SEC filing metadata
- accession: 0001193125-22-279097
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312522279097/0001193125-22-279097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312522279097/d411939d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-279097
- JSON: https://secwatch.observer/filing/0001193125-22-279097.json
- Plain text: https://secwatch.observer/filing/0001193125-22-279097.txt

## Key facts
- Earnings Releases
  Atea Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312522279097/0001193125-22-279097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.